Detection of the level and the complement activating properties of autoantibodies against citrullinated peptides.

<p>The arginine or citrulline-containing form of fibrinogen β chain peptide (SGSG⁶⁰RPAPPPISGGGYRAR⁷⁴ vs. SGSG⁶⁰XPAPPPISGGGYXAX⁷⁴) (A) and filaggrin peptides (⁴⁵⁴TRGRS⁴⁵⁸K vs. ⁴⁵⁴TXGRS⁴⁵⁸K) (B) were coupled on beads and incubated with serum samples to detect peptide-specific IgG, IgM, IgA autoantibody levels and their complement activating properties. Median fluorescent intensity (MFI) values for arginine or citrulline-containing forms of the peptides in RA patient group (red lines) or the control group (blue lines) are shown in the upper panel. Significance level of differences between controls and RA patients were calculated only for the citrullinated peptides by Mann-Whitney test and the p-values are indicated in the upper panel as follow: * p-value<0.05; ** p-value<0.01, ***p-value<0.001. Spearman's Rho correlation coefficients calculated between anti-C3, anti-IgG, anti-IgM and anti-IgA MFI values are shown for citrullined (middle panels) or native (lower panels) form of the peptides, where non-significant correlations are indicated by (n.s.).</p

Demographics of the serum sample donors.

a<p>Median and ranges in brackets are shown, where applicable. DAS - disease activity score.</p

Level of EBNA-1 specific antibodies and their complement activation.

<p>EBNA-1 coupled beads were incubated with sera of RA patients and controls. <b><i>A</i></b><i>)</i> Levels of bound human IgG, IgM and IgA antibodies along with the degree of complement activation are plotted for the two groups. Mann-Whitney non-parametric statistical test was used to calculate the statistical difference between the two groups. <b><i>B</i></b><i>)</i> Signal intensities for anti-IgM, anti-IgA and anti-C3 for the controls (upper panel) and RA patients (lower panel) are plotted in a 3D graph. The tables show the Spearman's Rho correlation coefficients between anti-C3, anti-IgG, anti-IgM and anti-IgA signal intensities calculated separately for the control and RA patient groups. Only statistically significant (p-value<0.05) correlation coefficients are shown and non-significant correlations are indicated by (n.s.).</p

Complement activation by rheumatoid factors.

<p>Following incubation of human-IgG coupled beads in sera of RA patients or non-diseased controls, bound IgG-specific rheumatoid factors and deposited C3 fragments were detected. <b><i>A</i></b><i>)</i> Median fluorescence intensities (MFI) for anti-IgG, anti-IgM, anti-IgA and anti-C3 secondary antibodies are plotted separately for the RA patients and controls. Statistical differences between these two groups were calculated by Mann-Whitney non-parametric test. <b><i>B</i></b><i>)</i> Anti-IgA, anti-IgM and anti-C3 MFI values for the human-IgG coupled bead within RA patient group (Δ) and controls (▪) are plotted in a 3D graph for visualization of their correlation to each other. Anti-IgG MFI values are excluded from this plot since they not reveal a significant difference between the two groups. <b><i>C)</i></b> The table shows the Spearman's Rho correlation coefficients between anti-C3, anti-IgG, anti-IgM and anti-IgA MFI values in the entire sample cohort, where only statistically significant (p-value < 0.05) correlation coefficients are shown and non-significant correlations are indicated by (n.s.).</p

Dependence of complement activation on serum dilution rate.

<p>For measuring the background, classical, lectin & alternative and only alternative pathway activation, a serially diluted serum sample (1∶1–1∶160) was applied to empty, human IgG, human IgA and properdin-coupled beads, respectively. The assay buffer for serum dilution contained either Ca²⁺-Mg²⁺, which promotes complement activation, or EDTA, which blocks complement activation. Complement activation-driven C3 fragment deposition on beads was detected by PE-conjugated anti-human C3 antibody. Plots display for each serum dilution the respective median fluorescence intensity (MFI) value against varying concentrations of human IgG, human IgA and properdin coupled on beads. AU - arbitrary units</p

Schematic representation of assay workflow.

<p><b>A</b>) Serum samples are diluted 1∶10, either in a Ca²⁺-Mg²⁺ containing assay buffer for detection of complement activation, or in an EDTA containing assay buffer for antibody detection. B) The samples are pre-adsorbed against neutravidin-specific antibodies. <b>C</b>) A mixture of beads coupled to various antigens is distributed into a 384-well plate and the pre-adsorbed samples are added to the bead array. <b>D</b>) Complement activation driven C3 deposition and different antibody isotypes are detected in parallel with fluorescently labeled secondary antibodies dispensed into individual wells of each quadrant of the 384-well plate.</p